Skip to main content

Illuminate your CMS Medicare quality program with an analytics-first strategy

Healthcare providers face difficult choices that can pit their number one priority ─ care quality ─ against the need to reduce costs and increase efficiency. Healthcare providers can achieve all of these goals using data analytics.

An analytics-first strategy enables hospitals, health systems and state hospital associations to make data-informed decisions, not best guesses. This proactive approach can illuminate trends and provide real-time insights that are often hidden or seen too late to change outcomes.
Data from your Medicare quality programs tell a compelling story, 24 hours a day, 365 days a year. DataGen uses Medicare impact modeling, expert analysis and visualizations to reveal data-informed narratives about your performance on three CMS programs:

  • Value-Based Purchasing (VBP);
  • Readmission Reduction Program (RRP); and
  • Hospital-Acquired Conditions (HAC) Reduction Program.

Do you know your organization’s stories?

The biggest and best tool in your healthcare management toolkit: Data

DataGen data analytics can help you:

  • reduce the negative, avoidable impacts of CMS penalties;
  • ensure more revenue flows to your organization; and
  • forewarn of regulatory impacts that make the difference between positive or negative outcomes for patients, providers and your community.

The DataGen Medicare FFS Quality Suite helps you identify improvement strategies by drawing out projected quality program impacts and performance trends, and enabling deep comparisons.

DataGen can help you monitor your hospital’s national peer percentile rank, foretell future-state revenue and gain more under Medicare quality programs.

Who wouldn’t want to stay ahead of that?

Take a peek at the data insights you may be missing

Each year, CMS adjusts payments for the acute care inpatient hospital setting based on performance in the VBP, RRP and HAC programs. DataGen’s most recent analysis compared these impacts for federal fiscal years 2021 to 2023.*

For RRP in FFY 2023, DataGen estimated a total loss across the country of $320 million due to poor performance on readmission quality measures. The map below shows state-by-state percentage impacts.

FFY 2023 RRP Percent Impact on Base Operating Dollars

*Note: CMS is neither penalizing nor rewarding hospitals for FFYs 2022 and 2023 for VBP due to the COVID-19 pandemic. For the same reason, CMS is not penalizing hospitals for the FFY 2023 HAC program.


Customized data stories at your fingertips

DataGen Medicare FFS Quality Suite enables you to select filters that narrow (e.g., specific facility) or broaden (e.g., market, region, state or nation) your data. Report toggles can instantly shift the data story. Other filters — for example, potential Medicare cuts, condition revenue and estimated impacts — create user-selected granularity and add customized storytelling to reporting.

DataGen’s visualization platform also contains dozens of native reports, so your stories can be interesting and insightful from the start.

Data stories from current CMS headlines

DataGen pools data and insight comparisons from multiple sources, including regulatory, legislative, quality, financial and operations. This allows you to identify and address impacts quickly to improve patient outcomes.

Find out how an analytics-first approach can strengthen your organization’s healthcare management. Reach out to DataGen today.


Comments

Popular posts from this blog

BPCI Advanced – take advantage of the model extension now

The Bundled Payment for Care Improvement (BPCI) Advanced Model is now open for applications until May 31, 2023. This model provides a unique opportunity to acute care hospitals and physician group practices who are looking to: evaluate their bundle performance; rejoin if they have previously dropped out due to being under a convener; or take advantage of the changes to the model. With a small window to sign the participation agreement, you’ll need experts to process data quickly and accurately for evaluation. BPCI Advanced Program Details The Centers for Medicare & Medicaid Services (CMS) announced in October 2022 that this program will extend from January 2024 to December 2025. Data used for evaluation will be taken from the baseline period between October 2018 and September 2022. A participation agreement will be sent out in September 2023 and needs to be signed by October 2023 in order to participate. Those who apply before the May 31 deadline will benefit

BPCI Advanced Model Extension

CMS recently made several major announcements about the Bundled Payments for Care Improvement Advanced Model.  The model, which was due to expire at the end of 2023 (Model Year 6), will be extended for an additional two years through Dec. 31, 2025.  New applications will be accepted in 2023 for the two-year extension. Participants still active in Model Year 6 can continue without reapplying by signing an amended and restated participation agreement for Model Year 7.  New methodological changes will be implemented for Model Year 6, which starts on Jan. 1, 2023. Methodological changes include that: the CMS Discount Factor for medical clinical episodes will be reduced from 3% to 2%;  the Peer Group Trend Factor Adjustment cap for all clinical episodes will be reduced from 10% to 5%; the Major Joint Replacement of the Upper Extremity clinical episode category will become a multi-setting episode category by allowing episodes to be triggered when the procedure is performed in the hospital ou

You’ve been accepted to the Enhancing Oncology Model. Now what?

The Centers for Medicare and Medicaid Services Innovation Center recently announced approved applicants for the new Enhancing Oncology Model. If your facility has been selected by CMS, are you still weighing your options during the current baseline evaluation period?  Two deciding factors may include the program data that CMS provides and whether EOM is enough of an improvement over the prior Oncology Care Model to make your investment worthwhile. Another factor to consider: Will you have the resources in place to conduct a baseline evaluation before EOM’s program start on July 1, 2023? How EOM differs from OCM EOM aims to improve the coordination of oncology care, drive practice transformation and reduce Medicare fee-for-service spending through episode-based payment. It includes three major updates: Fewer cancer types. Compared with OCM’s 21, EOM will be limited to seven common cancer types: breast, prostate, lung, small intestine/colorectal, multiple myeloma, lymphoma and chronic le